1132
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
GASTRITS: ETIOLOGY AND TREATMENT
Jabborov Sherbek Otabek o’g’li
Asian International University, Bukhara, Uzbekistan.
https://doi.org/10.5281/zenodo.15070415
Abstract.
Gastritis refers to the inflammation of the gastric mucosa and is often used to
describe the abnormal appearance of abnormal gastric mucosa on endoscopy or
radiology. Gastritis encompasses infectious or immunological inflammation of the gastric
mucosa and the host's response. Histopathological evidence of inflammation in the stomach
lining is essential to diagnose this condition. Gastropathy is characterized as a gastric mucosal
disorder without
inflammation,
often
featuring
epithelial
injury
and
subsequent
regeneration. Gastritis and gastropathy are not mutually exclusive conditions and might
sometimes coexist. In clinical practice, gastritis may be accompanied by signs of mucosal injury,
whereas gastropathy may show some evidence of an inflammatory reaction in the gastric
mucosa. Gastritis can be classified based on the acuity of the condition (acute versus chronic),
the histological features of the inflammation, or its etiology. Although there is no universally
accepted categorization and classification of gastritis, it is crucial to understand the histological
characteristics and etiological factors associated with the different types of gastritis to
comprehend their presentation and classification. Appropriate histological evaluation is also
essential in devising management plans for this disease. This review discusses the histological
and morphological presentations of gastritis, assesses their prognostic significance, and outlines
the guideline-recommended management approaches for these conditions. The primary objective
of this topic is to improve patient outcomes by enhancing the competence of healthcare
providers.
Keywords:
Inflammation, gastropathy, mucosal disorder, epithelial injury, subsequent
regeneration, inflammatory reaction.
ГАСТРИТЫ: ЭТИОЛОГИЯ И ЛЕЧЕНИЕ
Аннотация.
Гастрит относится к воспалению слизистой оболочки желудка и
часто используется для описания аномального вида аномальной слизистой оболочки
желудка при эндоскопии или рентгенологии. Гастрит охватывает инфекционное или
иммунологическое воспаление слизистой оболочки желудка и реакцию хозяина.
Гистопатологические доказательства воспаления в слизистой оболочке желудка
необходимы для диагностики этого состояния. Гастропатия характеризуется как
расстройство слизистой оболочки желудка без воспаления, часто с повреждением
эпителия и последующей регенерацией. Гастрит и гастропатия не являются
взаимоисключающими состояниями и иногда могут сосуществовать. В клинической
1133
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
практике гастрит может сопровождаться признаками повреждения слизистой
оболочки, тогда как гастропатия может показывать некоторые признаки
воспалительной реакции в слизистой оболочке желудка. Гастрит можно
классифицировать на основе остроты состояния (острый или хронический),
гистологических особенностей воспаления или его этиологии. Хотя не существует
общепринятой категоризации и классификации гастрита, крайне важно понимать
гистологические характеристики и этиологические факторы, связанные с различными
типами гастрита, чтобы понять их проявления и классификацию. Соответствующая
гистологическая оценка также имеет важное значение при разработке планов лечения
этого заболевания. В этом обзоре обсуждаются гистологические и морфологические
проявления гастрита, оценивается их прогностическое значение и излагаются
рекомендуемые в руководствах подходы к лечению этих состояний. Основной целью этой
темы является улучшение результатов лечения пациентов путем повышения
компетентности поставщиков медицинских услуг.
Ключевые слова:
воспаление, гастропатия, нарушение слизистой оболочки,
повреждение эпителия, последующая регенерация, воспалительная реакция.
Introduction
Gastritis is the inflammation of the gastric mucosa and is often used to describe the
abnormal appearance of abnormal gastric mucosa on endoscopy or radiology. Gastritis
encompasses infectious or immunological inflammation of the gastric mucosa and the host
response. Histopathological evidence of inflammation in the stomach lining is essential to
diagnose this condition. Gastropathy is a gastric mucosal disorder without inflammation,
featuring epithelial injury and subsequent regeneration. Gastritis and gastropathy are not
mutually exclusive conditions and might sometimes coexist. In clinical practice, gastritis may be
accompanied by signs of mucosal injury, whereas gastropathy may present with an inflammatory
reaction in the gastric mucosa.
Gastritis is classified based on the acuity of the condition (acute versus chronic), the
histological features of inflammation, or the etiology. Although the categorization and
classification of gastritis are not universally accepted, understanding the histological
characteristics and etiological factors associated with the different types of gastritis is essential.
Appropriate histological evaluation is also essential in devising management plans for
this disease. The primary objective is to equip treating clinicians with the ability to improve
patient outcomes through early intervention.
1134
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
Etiology
Acute Gastritis
Acute gastritis is temporary stomach lining inflammation caused by stress on the gastric
mucosa, manifesting as either hemorrhagic or non-hemorrhagic symptoms. This condition can
develop due to various factors, including uremia, ischemia, shock, corrosive agents, medications,
radiation, trauma, severe burns, sepsis, or alkaline-bile reflux. Certain infections, such as
enteroviruses, can also cause a self-limited episode of gastritis. Acute gastritis may result from
reduced gastric mucus secretion, mucosal barrier disruption, or decreased mucosal blood flow,
depending on the underlying cause.
Chronic Gastritis
Chronic gastritis is categorized into 2 forms—atrophic and non-atrophic. The primary
cause of chronic gastritis is a
Helicobacter pylori
infection, which typically starts with a non-
atrophic morphology. The non-atrophic form of chronic gastritis can progress to atrophic without
treatment. The most common cause of atrophic chronic gastritis is autoimmune gastritis, though
the etiology remains unclear. Autoimmune gastritis exhibits a chronic mononuclear inflammation
accompanied by severe atrophic gastritis, which usually affects the corpus, along with the
presence of autoantibodies against parietal cells or the intrinsic factor. However, whether
autoimmune gastritis is an independent disorder or if an
H pylori
infection triggers the
autoimmune response in susceptible individuals is unclear.
Reactive Gastritis
Reactive gastritis or gastropathy has numerous causative factors with acute gastritis.
Reactive gastritis may be caused by specific medications, alcohol consumption, radiation
exposure, and duodenal (bile) reflux. These causative agents lead to histological mucosal lesions
characterized by low-grade inflammation of the gastric mucosa. Although usually asymptomatic,
they are revealed through endoscopy, often showing multiple erosions or ulcers without signs of
atrophic changes. The use of immune checkpoint inhibitors to treat various malignancies has
contributed to the incidence of reactive gastritis, although the condition remains considerably
rare.
The Sydney System of Classification for Gastritis
The Histological Division of the Sydney System was introduced in 1990 and has since
become the most widely cited classification system for the morphological features of gastritis in
endoscopic biopsies. This system conveys information about the type, severity, and extent of
gastric pathology. The classification system conveys the topography of gastritis, which can be
restricted to the antrum or corpus or involve the entire stomach (pan gastritis).
If the etiology of the disease is known, this is added as a prefix to denote the topography.
1135
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
For instance, the label "autoimmune corpus gastritis" is used if the disease is
autoimmune. The Sydney System of Classification further delineates 5 graded morphological
variables that may be added as a suffix to the core topography. These variables include the type
or chronicity of inflammation, gastritis activity, intestinal metaplasia, the extent of atrophy, and
the presence or absence of
Heliobacter pylori
. The morphological features are graded as absent,
mild, moderate, or severe. The Sydney System of Classification recommends at least 2 random
biopsies from both the antrum and corpus, along with an additional biopsy from the incisura
angularis. Although the classification system provides a standardized and concise means of
documenting the extent and severity of gastritis, the method for predicting or forecasting future
morphological changes is impossible.
Classification of Gastritis Based on Etiological Factors
An alternative approach to classifying gastritis considers the etiology and chronicity of
the inflammation. This approach categorizes gastritis into 3 main subtypes—acute, chronic, and
special. Infectious gastritis is most commonly attributed to the global prevalence of
H
pylori
infection. Other types of infectious gastritis include phlegmonous gastritis (caused by
pyogenic bacteria), mycobacterial gastritis (caused by
Mycobacterium tuberculosis
), syphilitic
gastritis, viral gastritis (caused by cytomegalovirus and herpes simplex virus).
Granulomatous gastritis is a special gastritis observed in patients with Crohn disease and
sarcoidosis. Lymphocytic gastritis, collagenous gastritis, and eosinophilic gastritis are additional
special subtypes of gastritis with unclear etiologies. Lymphocytic and collagenous gastritis have
been associated with celiac disease, whereas eosinophilic gastritis has a strong connection to
atopic conditions and food allergens.
According to the 2015 Kyoto Consensus Conference, a classification of gastritis based on
etiological factors is outlined as follows:
Autoimmune gastritis
Infectious gastritis
o
Gastric phlegmon
o
Bacterial gastritis
H pylori
-induced
Enterococcal
Mycobacterial
o
Viral gastritis
Cytomegaloviral
Enteroviral
o
Fungal gastritis
1136
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
o
Parasitic gastritis
Gastric anisakiasis
Cryptosporidium
Gastric
Strongyloides stercoralis
Gastritis due to other diseases
o
Crohn disease
o
Sarcoidosis
o
Vasculitis
Gastritis due to external causes
o
Alcoholism
o
Radiation
o
Chemicals
Special gastritis
o
Allergic gastritis
o
Gastritis due to biliary reflux
o
Lymphocytic gastritis
o
Ménétrier disease
o
Eosinophilic gastritis
Epidemiology
Determining the incidence of acute gastritis can be challenging due to the common
causes, such as enterovirus infections, which typically result in mild and self-limited episodes
that go unreported. Other factors leading to acute gastritis, such as sepsis, ischemia, and caustic
injury, are relatively rare compared to chronic
H pylori–
associated gastritis and chronic atrophic
(autoimmune) gastritis. Recent data demonstrates chronic atrophic gastritis is estimated to affect
approximately 25% of the global population. Furthermore, the risk of developing chronic
atrophic gastritis is about 2.4 times higher in patients with
H pylori.
In Western populations, a declining incidence of infectious gastritis is thought to be
caused by an increasing prevalence of autoimmune gastritis. Autoimmune gastritis is more
prevalent in women and older individuals, with estimated rates ranging from 2,5% to 5,5%.
However, the available data may have limited reliability. Chronic
H pylori–
associated
nonatrophic gastritis continues to be highly prevalent in developing countries. In Western
populations, the prevalence of
H pylori
infection in children is approximately 15%, whereas the
prevalence is 54% in developing countries. The prevalence of
H pylori
infection in developing
countries varies significantly based on geographical region and socioeconomic conditions.
1137
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
Treatment / Management
Approach to Treatment
As mentioned earlier, eradicating
H pylori
is recommended for all patients with evidence
of gastritis on diagnostic testing. Furthermore, eradication therapy is the initial treatment option
for patients with dyspepsia who have a documented
H pylori
infection. In addition,
H
pylori
eradication therapy is indicated in patients with peptic ulcer disease, functional dyspepsia,
idiopathic thrombocytopenic purpura (ITP), unexplained iron-deficiency anemia, and in cases
where long-term nonsteroidal anti-inflammatory drug treatment is anticipated, particularly in
patients with a history of peptic ulcer disease. In patients with functional dyspepsia, eradication
therapy has a limited impact on symptom relief. Nonetheless, the therapy is advantageous in
mitigating the risk of peptic ulcer disease.
Eradication therapy for
H pylori
in patients with non-atrophic chronic gastritis is highly
recommended to promote healing and reduce the risk of gastric cancer. For patients with atrophic
gastritis, eradication therapy targeted at the organism may result in partial regression of the
gastritis and offer some potential benefits. Although the eradication therapy in patients with
intestinal metaplasia does not reverse the metaplastic changes, the progression to neoplasia is
slowed without reducing the overall risk of gastric cancer. Therefore, a cautious or weak
recommendation is considered in this context.
The management of chronic gastritis in patients who initially test negative for
H
pylori
lacks standardized guidelines and tends to exhibit significant variability. Empirical use of
proton-pump inhibitors (PPIs) has demonstrated effectiveness in alleviating symptoms for these
patients. According to current guidelines, empiric PPI therapy is recommended for individuals
aged younger than 60 with dyspepsia if they test negative for
H pylori
or experience persistent
symptoms despite undergoing eradication therapy. Patients who do not experience relief from
these treatments may be considered for prokinetic therapy or tricyclic antidepressants. Notably,
the supporting evidence is low-to-moderate quality.
Currently, definitive treatment does not exist for patients with atrophic gastritis. The
pivotal aspect in treating patients with atrophic gastritis is the application of risk stratification
systems to assess the severity of the disease and determine the risk of gastric malignancies. For
this purpose, utilizing the Operative Link on Gastritis Assessment (OLGA) and Operative Link
on Gastric Intestinal Metaplasia Assessment (OLGIM) grading systems is recommended. Staging
gastritis using the OLGA and OLGIM systems, with a stage III or IV classification, is associated
with a significantly elevated risk of gastric cancer. This approach provides an easily translated
method for assessing attributable risk.
1138
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
These systems incorporate atrophy scores obtained through histological assessment of
gastric biopsies and consider atrophy topography to assign clinical stages.
Histological Grading of Gastritis
In normal gastric mucosa, an acceptable range is typically 3 to 6 lymphocytes, plasma
cells, or macrophages per high power field, or 2 to 3 cells located between foveolae. The degree
of increase from these numbers determines the severity of gastritis, which is graded as mild (+--),
moderate (++-), or marked (+++). Notably, this density measurement should be performed away
from
any
lymphoid
follicles,
as
they
could
be
related
to
an
underlying
H
pylori
infection. Lymphocytic gastritis occurs when more than 25 lymphocytes are observed per
100 epithelial cells within the glandular epithelium. The density of neutrophils measures the
activity of gastritis. The grading of gastritis activity is followed as neutrophils in the lamina
propria indicate mild (+--) activity, neutrophils within the epithelium denote moderate (++-)
activity, and neutrophils in the glandular lumen signify marked (+++) activity.
The discrepancy between the expected glands for the anatomical site of the gastric
mucosa and what is observed represents atrophy. A reduction or complete absence of glandular
units leads to collagen deposition in the lamina propria. Metaplastic changes involve the
replacement of normal glandular units with metaplastic and/or dysplastic units. A score of 1 is
allocated when a 2% to 35% loss of the glandular architecture or its metaplastic transformation
occurs, a score of 2 is assigned for a 35% to 67% loss, and a score of 3 is designated for a loss
exceeding 65%. The OLGA staging system categorizes gastritis into 5 stages, each associated
with a progressively higher risk of cancer, determined by the atrophy score. In addition, an
overall atrophy score based on topography is assigned, and these scores are tallied to determine
the corresponding OLGA stage. Although the OLGIM staging system relies solely on intestinal
metaplasia for the atrophy score, enhancing inter-observer reproducibility, a notable decrease in
sensitivity for identifying high-risk patients is apparent.
Patients classified as OLGA/OLGIM stage III or IV face a considerable risk of
developing gastric adenocarcinoma. As a result, regular surveillance endoscopy is strongly
recommended for these individuals to enhance the chances of detecting gastric cancer in the
early stages, enabling surgical treatment. The AGA recommends endoscopic surveillance every 3
years in these patients. Other clinical factors that should be considered when determining the
frequency of surveillance include a family history of gastric cancer, residence in regions with a
high incidence of gastric cancer, a history of persistent
H pylori
infection, smoking history, and
dietary factors.
1139
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
Conclusion
According to the Kyoto Global Consensus Conference, etiology is taken for reference in
the classification of gastritis. The etiological picture of long-standing gastritis can include both
environmental (e.g.
H. pylori
) and host-related (e.g. Autoimmunity) agents, potentially resulting
in the atrophic transformation of native gastric mucosa. Epidemiological evidence implicates the
atrophic microenvironment in
H. pylori
gastritis as a major factor responsible for the
etiopathogenesis of more than 85% of gastric malignancies.
The atrophic transformation of gastric mucosa gives rise to different histological
phenotypes, all of which have been biologically profiled and can be histologically scored. They
may also be associated with a range of functional changes, which can serve as (quantitative)
serological markers of the atrophic process. It is easy to imagine the atrophy-remodeled gastric
microbiota having a role as co-promoter in the atrophic cancer-prone microenvironment.
Over the coming years, we will see how this multidisciplinary approach can be optimized
for the purpose of designing global strategies for eradicating gastric cancer and implementing
patient-tailored prevention strategies. The available evidence does suggest that combining
primary and secondary prevention strategies can realistically succeed in cutting the
epidemiological impact of gastric cancer – the world’s fourth leading cause of cancer-related
death.
REFERENCES
1.
Vali o’g’li, M. S. KIDNEY CANCER: EPIDEMIOLOGY AND TREATMENT.
2.
Valiyevich, M. S. (2024). Specific Morphofunctional Characteristics of the Kidney Caused
by Brain Damage in Various Emergency Situations. Research Journal of Trauma and
Disability Studies, 3(4), 286-289.
3.
PROSTATE CANCER: PATHOLOGY AND TREATMENT. (2024). International Bulletin of
Medical Sciences and Clinical Research, 4(11), 65-70. https://doi.org/10.37547/
4.
MUSHAKLARNING
TARAQQIYOTI.
MUSHAKLARNING
YORDAMCHI
APPARATI.
TADQIQOTLAR. UZ
,
40
(3), 94-100.
5.
Narzulaeva,
U.
(2023).
Pathogenetic
Mechanisms
of
Microcirculation
disorders.
International Bulletin of Medical Sciences and Clinical Research
,
3
(10), 60-65.
6.
Narzullaeva, U. R., Samieva, G. U., & Samiev, U. B. (2020). The importance of a healthy
lifestyle in eliminating risk factors in the early stages of hypertension.
Journal Of
Biomedicine And Practice
, 729-733
1140
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
7.
Abdurashitovich,
Z.
F.
(2024).
APPLICATION
OF
MYOCARDIAL
CYTOPROTECTORS IN ISCHEMIC HEART DISEASES.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
39
(5), 152-159.
8.
Abdurashitovich, Z. F. (2024). SIGNIFICANCE OF BIOMARKERS IN METABOLIC
SYNDROME.
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(9),
409-413.
9.
Zikrillaev, F.A. (2024). Cardiorehabilitations from Physiotherapeutic Treatments in
Cardiovascular Diseases.
American Journal of Bioscience and Clinical Integrity
,
1
(10), 96-
102.
10.
Abdurashitovich, Z. F. (2024). Cardiovascular System. Heart. Aorta. Carotid Artery.
11.
Abdurashitovich, Z. F. (2024). MORPHO-FUNCTIONAL ASPECTS OF THE DEEP
VEINS OF THE HUMAN BRAIN.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ
ИДЕИ В МИРЕ
,
36
(6), 203-206.
12.
Abdurashitovich, Z. F. (2024). ASTRAGAL O’SIMLIGINING TIBBIYOTDAGI MUHIM
AHAMIYATLARI
VA
SOG’LOM
TURMUSH
TARZIGA
TA’SIRI.
Лучшие
интеллектуальные исследования
,
14
(4), 111-119.
13.
Abdurashitovich, Z. F. (2024). ODAM ANATOMIYASI FANIDAN SINDESMOLOGIYA
BO’LIMI HAQIDA UMUMIY MALUMOTLAR.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
41
(4), 37-45.
14.
Abdurashitovich, Z. F. (2024). THE IMPORTANCE OF THE ASTRAGAL PLANT IN
MEDICINE AND ITS EFFECT ON A HEALTHY LIFESTYLE.
ОБРАЗОВАНИЕ НАУКА
И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
41
(4), 88-95.
15.
Abdurashitovich, Z. F. (2024). Department of Syndesmology from the Science of Human
Anatomy General Information About.
Research Journal of Trauma and Disability
Studies
,
3
(3), 158-165.
16.
Abdurashitovich, Z. F. (2024). THE COMPLEXITY OF THE FUSION OF THE BONES
OF THE FOOT.
JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH
,
3
(5),
223-230.
17.
Abdurashitovich, Z. F. (2024). ANATOMICAL COMPLEXITIES OF JOINT BONES OF
THE HAND.
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(4),
198-206.
18.
Зикриллаев, Ф. А. (2024). АНАТОМИЧЕСКОЕ СТРОЕНИЕ ОРГАНОВ ДЫХАНИЯ
И ЕГО ЛИЧНЫЕ ХАРАКТЕРИСТИКИ.
TADQIQOTLAR. UZ
,
40
(3), 86-93.
1141
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
19.
Abdurashitovich, Z. F. (2024). MIOKARD INFARKTI UCHUN XAVF OMILLARINING
AHAMIYATINI ANIQLASH.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ
В МИРЕ
,
36
(5), 83-89.
20.
Abdurashitovich, Z. F. (2024). THE RELATIONSHIP OF STRESS FACTORS AND
THYMUS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
36
(6),
188-196.
21.
Toxirovna, E. G. (2024). QALQONSIMON BEZ KASALLIKLARIDAN HASHIMOTO
TIREODIT KASALLIGINING MORFOFUNKSIONAL O’ZIGA XOSLIGI.
Modern
education and development
,
16
(7), 120-135.
22.
Toxirovna, E. G. (2024). REVMATOID ARTRIT: BO’G'IMLAR YALLIG'LANISHINING
SABABLARI, KLINIK BELGILARI, OQIBATLARI VA ZAMONAVIY DAVOLASH
YONDASHUVLARI.
Modern education and development
,
16
(7), 136-148.
23.
Эргашева, Г. Т. (2024). ОЦЕНКА КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ
ОРЛИСТАТА
У
БОЛЬНЫХ
ОЖИРЕНИЕМ
И
АРТЕРИАЛЬНОЙ
ГИПЕРТЕНЗИЕЙ.
Modern education and development
,
16
(7), 92-105.
24.
Ergasheva, G. T. (2024). THE SPECIFICITY OFAUTOIMMUNE THYROIDITIS IN
PREGNANCY.
European Journal of Modern Medicine and Practice
,
4
(11), 448-453.
25.
Эргашева, Г. Т. (2024).
ИССЛЕДОВАНИЕ ФУНКЦИИ ЩИТОВИДНОЙ ЖЕЛЕЗЫ ПРИ
ТИРЕОИДИТЕ ХАШИМОТО
.
Modern education and development
,
16
(7), 106-119.
26.
Toxirovna, E. G. (2024). GIPOFIZ ADENOMASINI NAZORAT QILISHDA
KONSERVATIV
JARROHLIK
VA
RADIATSIYA
TERAPIYASINING
UZOQ
MUDDATLI SAMARADORLIGI.
Modern education and development
,
16
(7), 79-91.
27.
ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY.
Valeology:
International Journal of Medical Anthropology and Bioethics
,
2
(09), 106-111.
28.
Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune
Thyroiditis.
American Journal of Bioscience and Clinical Integrity
,
1
(10), 43-50.
29.
Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN
PATIENTS WITH TYPE 2 DIABETES.
TADQIQOTLAR. UZ
,
40
(3), 55-62.
30.
Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN
PATIENTS
WITH
TYPE
2
DIABETES
MELLITUS
WITH
COMORBID
DISEASES.
TADQIQOTLAR. UZ
,
40
(3), 71-77.
31.
Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB
CHIQARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI.
TADQIQOTLAR.
UZ
,
40
(3), 63-70.
1142
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
32.
Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI
BO’LGAN BEMORLARDA GLIKEMIK NAZORAT.
TADQIQOTLAR. UZ
,
40
(3), 48-54.
33.
Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE)
IN TYPE 2 DIABETES.
JOURNAL OF HEALTHCARE AND LIFE-SCIENCE
RESEARCH
,
3
(5), 210-216.
34.
Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE
TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS.
EUROPEAN
JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(4), 171-177.
35.
Эргашева, Г. Т. (2024). Эффект Применения Бигуанида При Сахарным Диабетом 2
Типа И Covid-19.
Research Journal of Trauma and Disability Studies
,
3
(3), 55-61.
36.
Saloxiddinovna, X. Y. (2024). Modern Views on the Effects of the Use of Cholecalciferol
on the General Condition of the Bod.
JOURNAL OF HEALTHCARE AND LIFE-SCIENCE
RESEARCH
,
3
(5), 79-85.
37.
Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И
КЛИНИЧЕСКИЕ АСПЕКТЫ СТРОЕНИЯ И РАЗВИТИЯ ЯИЧНИКОВ (ОБЗОР
ЛИТЕРАТУРЫ).
TADQIQOTLAR. UZ
,
40
(5), 188-198.
38.
Халимова, Ю. С. (2024). Морфологические Особенности Поражения Печени У
Пациентов С Синдромом Мэллори-Вейса.
Journal of Science in Medicine and
Life
,
2
(6), 166-172.
39.
Xalimova, Y. S. (2024). Morphology of the Testes in the Detection of Infertility.
Journal of
Science in Medicine and Life
,
2
(6), 83-88.
40.
KHALIMOVA, Y. S. (2024). MORPHOFUNCTIONAL CHARACTERISTICS OF
TESTICULAR AND OVARIAN TISSUES OF ANIMALS IN THE AGE
ASPECT.
Valeology: International Journal of Medical Anthropology and Bioethics
,
2
(9),
100-105.
41.
Salokhiddinovna, K. Y. (2024). IMMUNOLOGICAL CRITERIA OF REPRODUCTION
AND VIABILITY OF FEMALE RAT OFFSPRING UNDER THE INFLUENCE OF
ETHANOL.
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(10),
200-205.
42.
Salokhiddinovna, K. Y., Saifiloevich, S. B., Barnoevich, K. I., & Hikmatov, A. S. (2024).
THE INCIDENCE OF AIDS, THE DEFINITION AND CAUSES OF THE
DISEASE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2),
195-205.
1143
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 3
43.
Nematilloevna, K. M., & Salokhiddinovna, K. Y. (2024).
IMPORTANT FEATURES IN THE
FORMATION OF DEGREE OF COMPARISON OF ADJECTIVES IN LATIN.
ОБРАЗОВАНИЕ
НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 150-157.
44.
Saloxiddinovna, X. Y., & Ne’matillaevna, X. M. (2024).
FEATURES OF THE STRUCTURE
OF THE REPRODUCTIVE ORGANS OF THE FEMALE BODY.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 179-183.
45.
Хафизова, М. Н., & Халимова, Ю. С. (2024). ИСПОЛЬЗОВАНИЕ ЧАСТОТНЫХ
ОТРЕЗКОВ В НАИМЕНОВАНИЯХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ В
ФАРМАЦЕВТИКЕ.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
55
(2), 172-178.
46.
Хафизова, М. Н., & Халимова, Ю. С. (2024). МОТИВАЦИОННЫЕ МЕТОДЫ ПРИ
ОБУЧЕНИИ ЛАТЫНИ И МЕДИЦИНСКОЙ ТЕРМИНОЛОГИИ.
ОБРАЗОВАНИЕ
НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 165-171.
47.
Халимова, Ю. С., & Хафизова, М. Н. (2024). ОСОБЕННОСТИ СОЗРЕВАНИЕ И
ФУНКЦИОНИРОВАНИЕ
ЯИЧНИКОВ.
ОБРАЗОВАНИЕ
НАУКА
И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 188-194.
48.
Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ АСПЕКТЫ ЛИЦ
ЗЛОУПОТРЕБЛЯЮЩЕЕСЯ ЭНЕРГЕТИЧЕСКИМИ НАПИТКАМИ.
TADQIQOTLAR.
UZ
,
40
(5), 199-207.
49.
Халимова, Ю. С., & Хафизова, М. Н. (2024). кафедра Клинических наук Азиатский
международный
университет
Бухара,
Узбекистан.
Modern
education
and
development
,
10
(1), 60-75.
50.
Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ
ЗАБОЛЕВАНИЙ
ВНУТРЕННИХ
ОРГАНОВ
У
ЛИЦ,
СТРАДАЮЩИХ
АЛКОГОЛЬНОЙ ЗАВИСИМОСТЬЮ.
TADQIQOTLAR. UZ
,
40
(5), 240-250.
51.
Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И
КЛИНИЧЕСКИЕ АСПЕКТЫ ФОРМИРОВАНИЯ КОЖНЫХ ПОКРОВОВ.
Modern
education and development
,
10
(1), 76-90.
52.
Khalimova, Y. S. (2024). Features of Sperm Development: Spermatogenesis and
Fertilization.
American Journal of Bioscience and Clinical Integrity
,
1
(11), 90-98.
53.
Salokhiddinovna, K. Y., & Nematilloevna, K. M. (2024). MODERN MORPHOLOGY OF
HEMATOPOIETIC ORGANS.
Modern education and development
,
16
(9), 50-60.
54.
Khalimova, Y. (2025). MORPHOLOGY OF PATHOLOGICAL FORMS OF
PLATELETS.
Modern Science and Research
,
4
(2), 749-759.
